SAN DIEGO—Kihara James, the Principal Accounting Officer of Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), recently reported a sale of company shares. According to a filing with the Securities and Exchange Commission, James sold 4,073 shares of common stock on November 19, 2024, at a weighted average price of $16.81, totaling approximately $68,467.
The transactions were part of mandatory sales to cover withholding taxes related to the vesting of restricted stock units. These sales were executed in compliance with Rule 10b5-1(c) under the Exchange Act. Following these transactions, James holds 19,863 shares of Acadia Pharmaceuticals’ common stock directly.
This disclosure provides insight into insider activities at Acadia Pharmaceuticals, a San Diego-based company specializing in pharmaceutical preparations.
In other recent news, ACADIA Pharmaceuticals (NASDAQ:ACAD) has disclosed its third-quarter earnings for 2024, with a spotlight on the robust performance of its commercial franchises, DAYBUE and NUPLAZID. The earnings call, led by a team of executives including CEO Catherine Owen-Adams and CFO Mark Schneyer, also provided updates on the company's pipeline program. The company has expressed confidence in the continued market performance and growth of DAYBUE and NUPLAZID. Additionally, ACADIA Pharmaceuticals has ongoing research and development efforts, with promising advances in the pipeline hinting at potential future growth. The Q&A session following the presentation offered further insights into the company's performance and expectations. Notably, the call did not disclose any specific challenges or misses. These are among the recent developments for ACADIA Pharmaceuticals.
InvestingPro Insights
To provide additional context to Kihara James's recent stock sale, let's examine some key financial metrics and insights from InvestingPro for Acadia Pharmaceuticals Inc. (NASDAQ:ACAD).
Acadia's market capitalization stands at $2.7 billion, reflecting its significant presence in the pharmaceutical sector. The company's P/E ratio of 20.84 suggests that investors are willing to pay a premium for its earnings, potentially due to growth expectations.
One of the most notable InvestingPro Tips is that Acadia holds more cash than debt on its balance sheet. This strong financial position aligns with another tip indicating that the company's liquid assets exceed short-term obligations. These factors contribute to Acadia's financial stability, which is crucial for a pharmaceutical company investing in research and development.
Furthermore, Acadia's revenue growth is impressive, with a 47.06% increase in the last twelve months as of Q3 2024. This robust growth is complemented by a healthy gross profit margin of 62.64%, demonstrating the company's ability to maintain profitability while expanding its operations.
InvestingPro Tips also reveal that analysts expect Acadia's net income to grow this year, and the company is predicted to be profitable. This positive outlook may explain why insiders like Kihara James might engage in stock transactions, potentially for personal financial planning rather than as a reflection on the company's prospects.
It's worth noting that Acadia does not pay a dividend to shareholders, which is common for growth-oriented pharmaceutical companies that reinvest profits into research and development.
For investors seeking a more comprehensive analysis, InvestingPro offers additional tips and insights. In fact, there are 5 more InvestingPro Tips available for Acadia Pharmaceuticals, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.